Home » Stocks » HEPA

Hepion Pharmaceuticals, Inc. (HEPA)

Stock Price: $2.31 USD 0.01 (0.43%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Pre-market: $2.25 -0.06 (-2.60%) Jan 22, 5:49 AM
Market Cap 73.98M
Revenue (ttm) n/a
Net Income (ttm) -17.30M
Shares Out 9.03M
EPS (ttm) -10.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $2.31
Previous Close $2.30
Change ($) 0.01
Change (%) 0.43%
Day's Open 2.30
Day's Range 2.23 - 2.35
Day's Volume 588,222
52-Week Range 1.15 - 5.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 2 weeks ago

EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven th...

Accesswire - 3 weeks ago

CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON...

Accesswire - 3 weeks ago

- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dos...

Accesswire - 4 weeks ago

- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) f...

Zacks Investment Research - 1 month ago

Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Hepion (HEPA) stock based on the movements in the options market lately.

Seeking Alpha - 6 months ago

Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

Benzinga - 6 months ago

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading higher after the company reported its CRV431 demonstrated efficacy in Kidney Fibrosis.

Seeking Alpha - 10 months ago

The coronavirus pandemic has delivered a shock to our economy, and the severity will be dependent on whether the "curve is flattened".

Other stocks mentioned: AHPI, GILD, GNMK, NVS, REGN
Zacks Investment Research - 1 year ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: HSII, JBGS, NWBI, THG
Zacks Investment Research - 1 year ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: KOF, NWBI, RUBI, THG
Seeking Alpha - 1 year ago

Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs

Seeking Alpha - 1 year ago

Hepion Pharmaceuticals And Neoleukin Therapeutics: Two Micro Cap Pharmaceutical Stocks Priced For "Non Success" With Promising Drugs

Benzinga - 1 year ago

Shares of Hepion Pharmaceuticals Inc (NASDAQ: HEPA), formerly ContraVir Pharma, are ripping higher after the thinly-traded, nano-cap biotech announced results from an animal study of its lead ...

Market Watch - 1 year ago

Shares of Hepion Pharmaceuticals Inc. rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of it...

Zacks Investment Research - 1 year ago

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Other stocks mentioned: BBC, BBP, BTEC, SBIO
Market Watch - 1 year ago

Shares of Hepion Pharmaceuticals Inc. HEPA, -4.94% soared 45% in very active premarket trading Thursday, after the biopharmaceutical company published data showing potential for its CRV431 to ...

About HEPA

Hepion Pharmaceuticals, a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hep... [Read more...]

Industry
Biotechnology
CEO
Robert Foster
Employees
12
Stock Exchange
NASDAQ
Ticker Symbol
HEPA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for HEPA stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 332.90% from the latest price.

Price Target
$10.00
(332.90% upside)
Analyst Consensus: Buy